Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Body shape and metabolic abnormalities in Thai HIV-infected patients.

Homsanit M, Nelson KE, Sonjai A, Anekthananon T, Suwanagool S, Cofrancesco J Jr.

AIDS Res Hum Retroviruses. 2007 Nov;23(11):1314-21. doi: 10.1089/aid.2007.0013.

PMID:
18184072
2.

Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy.

Gervasoni C, Ridolfo AL, Trifirò G, Santambrogio S, Norbiato G, Musicco M, Clerici M, Galli M, Moroni M.

AIDS. 1999 Mar 11;13(4):465-71.

PMID:
10197374
3.

HIV lipodystrophy: prevalence, severity and correlates of risk in Australia.

Miller J, Carr A, Emery S, Law M, Mallal S, Baker D, Smith D, Kaldor J, Cooper DA.

HIV Med. 2003 Jul;4(3):293-301.

4.

Altered fat distribution in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy.

Mulligan K, Tai VW, Algren H, Abrams DI, Leiser RJ, Lo JC, Schambelan M.

J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):443-8.

PMID:
11391163
5.

A prospective study of body fat redistribution, lipid, and glucose parameters in HIV-infected patients initiating combination antiretroviral therapy.

Walmsley S, Cheung AM, Fantus G, Gough K, Smaill F, Azad, Diong C, Raboud J.

HIV Clin Trials. 2008 Sep-Oct;9(5):314-23. doi: 10.1310/hct0905-314.

PMID:
18977720
6.

Lipid profiles of Thai adult HIV-infected patients receiving protease inhibitors.

Hiransuthikul N, Hiransuthikul P, Kanasook Y.

Southeast Asian J Trop Med Public Health. 2007 Jan;38(1):69-77.

PMID:
17539249
7.

Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naive HIV-infected children.

Bitnun A, Sochett E, Babyn P, Holowka S, Stephens D, Read S, King SM.

AIDS. 2003 Jun 13;17(9):1319-27.

PMID:
12799553
8.

Antiretroviral therapy affects the composition of weight loss in HIV infection: implications for clinical nutrition.

Maia BS, Engelson ES, Wang J, Kotler DP.

Clin Nutr. 2005 Dec;24(6):971-8. Epub 2005 Aug 10.

PMID:
16095765
9.

Metabolic abnormalities in adult HIV infected population on antiretroviral medication in Malaysia: a cross-sectional survey.

Hejazi N, Rajikan R, Choong CL, Sahar S.

BMC Public Health. 2013 Aug 15;13:758. doi: 10.1186/1471-2458-13-758.

10.

Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences.

Hammond E, McKinnon E, Nolan D.

Clin Infect Dis. 2010 Sep 1;51(5):591-9. doi: 10.1086/655765.

PMID:
20645860
11.

Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors.

Melvin AJ, Lennon S, Mohan KM, Purnell JQ.

AIDS Res Hum Retroviruses. 2001 Aug 10;17(12):1117-23.

PMID:
11522181
12.

Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.

Hansen AB, Lindegaard B, Obel N, Andersen O, Nielsen H, Gerstoft J.

HIV Med. 2006 Jan;7(1):38-45.

13.

Leptin and adipose tissue maldistribution in HIV-infected male patients with predominant fat loss treated with antiretroviral therapy.

Estrada V, Serrano-Ríos M, Martínez Larrad MT, Villar NG, González López A, Téllez MJ, Fernández C.

J Acquir Immune Defic Syndr. 2002 Jan 1;29(1):32-40.

PMID:
11782587
14.

Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome.

Kosmiski LA, Kuritzkes DR, Lichtenstein KA, Glueck DH, Gourley PJ, Stamm ER, Scherzinger AL, Eckel RH.

AIDS. 2001 Oct 19;15(15):1993-2000.

PMID:
11600828
15.

Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.

Keiser PH, Sension MG, DeJesus E, Rodriguez A, Olliffe JF, Williams VC, Wakeford JH, Snidow JW, Shachoy-Clark AD, Fleming JW, Pakes GE, Hernandez JE; ESS40003 Study Team.

BMC Infect Dis. 2005 Jan 12;5:2.

16.

Long-term efficacy and safety of once-daily fosamprenavir 1400 mg boosted by ritonavir 100 mg: the BOLD100 study.

Blick G, Greiger-Zanlungo P, Gretz S, Han J, Dupree D, Garton T, Yau LH, Wine BC, Pakes GE; Boosting Once-daily Lexiva Delivery with ritonavir 100 mg QD [BOLD100] Study Team.

Int J STD AIDS. 2012 Mar;23(3):e18-22. doi: 10.1258/ijsa.2009.009161.

PMID:
22581890
17.

Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.

McComsey G, Bhumbra N, Ma JF, Rathore M, Alvarez A; First Pediatric Switch Study.

Pediatrics. 2003 Mar;111(3):e275-81.

PMID:
12612284
18.

Serum lipids and glucose abnormalities in HIV/AIDS patients on antiretroviral therapies.

Salami AK, Akande AA, Olokoba AB.

West Afr J Med. 2009 Jan;28(1):10-5.

PMID:
19662738
19.

High-sensitivity C-reactive protein levels in HIV-infected patients treated or not with antiretroviral drugs and their correlation with factors related to cardiovascular risk and HIV infection.

Guimarães MM, Greco DB, Figueiredo SM, Fóscolo RB, Oliveira AR Jr, Machado LJ.

Atherosclerosis. 2008 Dec;201(2):434-9. doi: 10.1016/j.atherosclerosis.2008.02.003. Epub 2008 Feb 15.

PMID:
18359028
20.

Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095).

Shikuma CM, Yang Y, Glesby MJ, Meyer WA 3rd, Tashima KT, Ribaudo HJ, Webb N, Bastow B, Kuritzkes DR, Gulick RM.

J Acquir Immune Defic Syndr. 2007 Apr 15;44(5):540-50.

PMID:
17245230

Supplemental Content

Support Center